Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Change in Cash (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Change in Cash for 15 consecutive years, with -$941000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash fell 20.49% year-over-year to -$941000.0, compared with a TTM value of $255000.0 through Sep 2025, up 102.49%, and an annual FY2024 reading of -$5.0 million, up 89.41% over the prior year.
  • Change in Cash was -$941000.0 for Q3 2025 at Alaunos Therapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $15.0 million in Q3 2021 and bottomed at -$23.3 million in Q2 2021.
  • Average Change in Cash over 5 years is -$6.0 million, with a median of -$5.9 million recorded in 2023.
  • The sharpest move saw Change in Cash plummeted 570.18% in 2023, then skyrocketed 252.29% in 2025.
  • Year by year, Change in Cash stood at -$15.7 million in 2021, then skyrocketed by 107.98% to $1.3 million in 2022, then tumbled by 570.18% to -$5.9 million in 2023, then soared by 89.94% to -$592000.0 in 2024, then crashed by 58.95% to -$941000.0 in 2025.
  • Business Quant data shows Change in Cash for TCRT at -$941000.0 in Q3 2025, $2.6 million in Q2 2025, and -$772000.0 in Q1 2025.